U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07412288) titled 'First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants' on Feb. 09.
Brief Summary: This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: KT-579
Oral drug
DRUG: Placebo
Oral drug
Recruitment Status: RECRUITING
Sponsor: Kymera Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....